Gastroesophageal reflux in children: Pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment

Pediatric Drugs

Volumn 4, Issue 10, 2002, Pages 673-685

  Gold, B D ^a   Freston, J W ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BETHANECHOL; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; DIGOXIN; DOMPERIDONE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PREDNISONE; PROKINETIC AGENT; PROPRANOLOL; PROTON PUMP INHIBITOR; RANITIDINE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ADOLESCENT; AREA UNDER THE CURVE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL RADIOGRAPHY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGASTRINEMIA; INFANT; LIFESTYLE; PARKINSONISM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCINTISCANNING; STOMACH PH; STOMACH SURGERY; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; VOMITING;

EID: 0036396730     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204100-00004     Document Type: Review

References (183)

1. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal oesophagus: a quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 325-30
2. Johnsson F, Joelsson B, Isberg P-E. Ambulatory 24 hour intraesophageal pH-monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987; 28: 1145-50
3. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122 (5): 1500-11
5. Heartburn across America: a Gallup Organization national survey. Princeton (NJ): Gallup Organization, 1988
6. Nelson SP, Chen EH, Syniar GM, et al., for the Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150-4
7. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569-72
8. Gibbons TE, Stockwell JA, Kreh RP, et al. The status of gastroesophageal reflux disease in hospitalized US children 1995-2000 [abstract]. J Pediatr Gastroenterol Nutr 2001; 33 (4): 197
9. Dahl M, Thommessen M, Rasmussen M, et al. Feeding and nutritional characteristics in children with moderate or severe cerebral palsy. Acta Paediatr 1996; 6: 697-701
10. Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 1996; 6: 877-82
11. Gisel EG, Birnbaum R, Schwartz S. Feeding impairments in children: diagnosis and effective intervention. Int J Orofacial Myology 1998; 24: 27-33
12. Schwarz SM, Corredor J, Fisher-Medina J, et al. Diagnosis and treatment of feeding disorders in children with developmental disabilities. Pediatrics 2001: 108: 671-6
13. Andze G, Brandt M, St-Vil D, et al. Diagnosis and treatment of gastroesophageal reflux in 500 children with respiratory symptoms: value of pH monitoring. J Pediatr Surg 1991; 26: 295-9
14. Tucci F, Resti M, Fontana R, et al. Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. J Pediatr Gastroenterol Nutr 1993; 17: 265-70
15. Martin ME, Grunstein MM, Larsen GL. The relationship of gastroesophageal reflux to nocturnal wheezing in children with asthma. Ann Allergy 1982; 49: 318-22
16. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001: 32 Suppl. 2: S1-31
17. Gustafsson PM, Kjellman NI, Tibbling L. A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux. Eur Respir J 1992; 5: 201-6
18. Balson BM, Kravitz EKS, McGeady SJ. Diagnosis and treatment of gastroesophageal reflux in children and adolescents with severe asthma. Ann Allergy Asthma Immunol 1998; 81: 159-64
19. Callahan CW. The diagnosis of gastroesophageal reflux in hospitalized infants: 1971-1995. J Am Osteopath Assoc 1998; 98: 32-4
20. Ashorn M, Ruuska T, Karikoski R, et al. The natural course of gastroesophageal reflux disease in children. Scand J Gastroenterol 2002; 37: 638-41
21. Carr MM, Nguyen A, Nagy M, et al. Clinical presentation as a guide to the identification of GERD in children. Int J Pediatr Otorhinolaryngol 2000; 54: 27-32
22. Ramesh P, Braden D, Dey S, et al. Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Caucasian predominant adolescent population [abstract]. Gastroenterology 2002; 122 (4): A-213
23. Ramesh P, Santiago M, Schmidt K, et al. Prevalence of gastroesophageal reflux disease symptoms in an African American predominant adolescent high school population [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: A194
24. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24-9
25. Treem WR, Davis PM, Hyams JS. Gastroesophageal reflux in the older child: presentation, response to treatment and long-term follow-up. Clin Pediatr (Phila) 1991; 30: 435-40
26. Kane RE, Sarr M, Foy TM. Omeprazole versus lansoprazole in the treatment of children with peptic esophagitis refractory to H2 antagonists [abstract]. Gastroenterology 1997; 112 Suppl. 4: A166
27. Bohmer CJ, Niezen-de Boer MC, Klinkenberg-Knol EC, et al. The prevalence of gastroesophageal reflux in institutionalized intellectually disabled individuals. Am J Gastroenterol 1999; 94: 804-10
28. Rogers B, Stratton P, Msall M, et al. Long-term morbidity and management strategies of tracheal aspiration in adults with severe developmental disabilities. Am J Ment Retard 1994; 98: 490-8
29. Werlin SL, Dodds WJ, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in children. J Pediatr 1980; 97: 244-9
30. Orenstein SR. Gastroesophageal reflux. Curr Probl Pediatr 1991; 21 (5): 193-241
31. Lagergren J, Bergstrom R, Lindgrena A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31
32. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 158: 2373-6
33. Euler AR, Ament ME. Value of esophageal manometric studies in the gastroesophageal reflux of infancy. Pediatrics 1977; 59: 58-61
34. Herbst JJ, Book LS, Bray PF. Gastroesophageal reflux in the "near miss" sudden infant death syndrome. J Pediatr 1978; 92: 73-5
35. Ze Hu F, Preston R, Post J, et al. Mapping of a gene of severe pediatric gastroesophageal reflux to chromosome 13q14. JAMA 2000; 284: 325-34
36. Vandenplas Y. The diagnosis and treatment of gastroesophageal reflux disease in infants and children. Ann Med 1993; 25: 323-8
37. Faubion W, Zein N. Gastroesophageal reflux in infants and children. Mayo Clin Proc 1998; 73: 166-73
38. Szarka LA, DeVault KR, Murray JA. Diagnosing gastroesophageal reflux disease. Mayo Clin Proc 2001; 76: 97-101
39. Gilger MA, Dietrich C, Gold B, et al. Does the endoscopic impression accurately predict histology in pediatric EGD [abstract]. Gastroenterology 2002; 122: A80
40. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease: current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14
41. Yaseen M, Casteel HB. Gastroesophageal reflux in children. J Ark Med Soc 1996; 92 (8): 390-6
42. Saxena V, Fienes L, Bland JM, et al. A short course of lansoprazole provides an accurate diagnostic test for symptomatic GORD [abstract]. Gut 1999; 44 Suppl. 2: A113
43. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Gastric polyps during long-term omeprazole treatment for gastroesophageal reflux disease [abstract]. Gastroenterology 1997; 112: A281
44. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9
45. Iacono G, Carroccio A, Cavataio F, et al. Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996; 97: 822-7
46. Hill DJ, Cameron DJ, Francis DE, et al. Challenge confirmation of late-onset reactions to extensively hydrolyzed formulas in infants with multiple food protein intolerance. J Allergy Clin Immunol 1995; 96: 386-94
47. Cavataio F, Iacono G, Montalto G, et al. Gastroesophageal reflux associated with cow's milk allergy in infants: which diagnostic examinations are useful. Am J Gastroenterol 1996; 91: 1215-20
48. Cavataio F, Iacono G, Montalto G, et al. Clinical and pH-metric characteristics of gastro-oesophageal reflux secondary to cows' milk protein allergy. Arch Dis Child 1996; 75: 51-6
49. Vandenplas Y, Sacre L. Milk-thickening agents as a treatment for gastroesophageal reflux. Clin Pediatr 1987; 26: 66-8
50. Bailey DJ, Andres JM, Danek GD, et al. Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux. J Pediatr 1987; 110: 187-9
51. Orenstein SR, Magill HL, Brooks P. Thickening of infant feedings for therapy of gastroesophageal reflux. J Pediatr 1987; 110: 181-6
52. Meyers WF, Herbst JJ. Effectiveness of positioning therapy for gastroesophageal reflux. Pediatrics 1982; 69: 768-72
53. Vandenplas Y, Scre-Smits L. Seventeen-hour continuous esophageal pH monitoring in the newborn: evaluation of the influence of position in asymptomatic and symptomatic babies. J Pediatr Gastroenterol Nutr 1985; 4: 356-61
54. Tobin JM, McCloud P, Cameron DJ. Posture and gastroesophageal reflux: a case for left lateral positioning. Arch Dis Child 1997; 76: 254-8
55. Oyen N, Markestad T, Skaerven R, et al. Combined effects of sleeping position and prenatal risk factors in sudden infant death syndrome: the Nordic Epidemiological SIDS Study. Pediatrics 1997; 100: 613-21
56. American Academy of Pediatrics. Task Force on Infant Sleep Position and Sudden Infant Death Syndrome. Changing concepts of sudden infant death syndrome: implications for infant sleeping environment and sleep position. Pediatrics 2000; 105: 650-6
57. Mattioli G, Repetto P, Carlini C, et al. Laparoscopic vs open approach for the treatment of gastroesophageal reflux in children. Surg Endosc 2002; 16: 750-2
58. Tovar JA, Olivares P, Diaz M, et al. Functional results of laparoscopic fundoplication in children. J Pediatr Gastroenterol Nutr 1998; 26: 429-31
59. Veit F, Schwagten K, Auldist AW, et al. Trends in the use of fundoplication in children with gastro-oesophageal reflux. J Paediatr Child Health 1995; 31: 121-6
60. Randolph J. Experience with the Nissen fundoplication for correction of gastroesophageal reflux in infants. Ann Surg 1983; 198: 579-84
61. Bensoussan AL, Yazbeck S, Carceller-Blanchard A. Results and complications of Toupet partial posterior wrap: 10 years' experience. J Pediatr Surg 1994; 29: 1215-7
62. Ahrens P, Heller K, Beyer P, et al. Antireflux surgery in children suffering from reflux-associated respiratory diseases. Pediatr Pulmonol 1999; 28: 89-93
63. Bergmeijer JH, Harbers JS, Molenaar JC. Function of pediatric Nissen-Rossetti fundoplication followed up into adolescence and adulthood. J Am Coil Surg 1997; 184: 259-61
64. Dunn JC, Lai EC, Webber MM, et al. Long-term quantitative results following fundoplication and antroplasty for gastroesophageal reflux and delayed gastric emptying in children. Am J Surg 1998; 175: 27-9
65. Caniano DA, Ginn-Pease ME, King DR. The failed antireflux procedure: analysis of risk factors and morbidity. J Pediatr Surg 1990; 25: 1022-6
66. Rothenberg SS. Experience with 220 consecutive laparoscopic Nissen fundoplication in infants and children. J Pediatr Surg 1998; 33: 274-8
67. Dalla Vecchia LK, Grosfeld JL, West KW, et al. Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients. Ann Surg 1997; 226: 315-21
68. Fonkalsrud EW, Ashcraft KW, Coran AG, et al. Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998; 101: 419-22
69. Hassall E. Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children. Am J Gastroenterol 1995; 90: 1212-20
70. Waring JP. Postfundoplication complications: prevention and management. Gastroenterol Clin North Am 1999; 28: 1007-19
71. Dall'Oglio L, Gatti C, Villa M, et al. A new and successful change in surgical treatment of gastroesophageal reflux in severely neurologically impaired children: Bianchi's procedure. Eur J Pediatr Surg 2000; 10: 291-4
72. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 148-54
73. Hassall E. Antireflux surgery in children: time for a harder look. Pediatrics 1998; 101: 467-8
74. Tsou VM, Young RM, Hart MH, et al. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87: 148-51
75. Woodard-Knight L, Fudge A, Teubner J, et al. Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 1992; 28: 257-9
76. Nurko S. Cisapride for the treatment of gastroestophageal reflux disease in children [letter]. J Pediatr Gastroenterol Nutr 1999; 29: 7
77. Cucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31: 21-5
78. Cucchiara S, Staiano A, Capozzi C, et al. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1987; 62: 454-7
79. Vandenplas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediatr Gastroenterol Nutr 1991; 12: 44-7
80. Scott RB, Ferreira C, Smith L. et al. Cisapride in pediatric gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1997; 25: 499-506
81. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther 1989; 11: 669-77
82. Leung C, Lai W. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res 1984; 36: 911-5
83. Machida HM, Forbes DA, Gall DG, et al. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988; 112: 483-7
84. De Loore I, Van Ravensteyn H, Amerychx I. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation: a comparison with metoclopramide. Postgrad Med J 1979; 55: 40-2
85. Bellissant E, Duhamel JF, Guillott M, et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin Pharmacol Ther 1997; 61: 377-84
86. Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr 1980; 96: 321-4
87. Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985; 40: 349-59
88. Bines JE, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400-5
89. Carroccio A, Iacono G, Montalto G, et al. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux - a double-blind randomized study versus placebo. Scand J Gastroenterol 1994; 29: 300-4
90. Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992; 121: 983-5
91. Merki HS, Wilder-Smith C, Walt R, et al. The cephalic and gastric phases of gastric acid secretion during H2 antagonist treatment. Gastroenterol 1991; 100: 599-606
92. Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine. Aliment Pharmacol Ther 1990; 4 Suppl. 1: 29-45
93. Lachman L, Howden C. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57-61
94. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6 (9 Suppl.): S491-505
95. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related disease. J Am Pharm Assoc 2000; 40: 52-62
96. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 268-80
97. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol 2001; 13 Suppl. 1: S5-11
98. Blum RA, Shi H, Karol MD. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-23
99. Jones RH, Baxter G. Lansoprazole 30mg daily versus ranitidine 150mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 541-6
100. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810
101. Huang J-Q, Hunt RH. Meta-analysis of comparative trials for healing erosive esophagitis (EE) with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) [abstract]. Gastroenterology 1998; 114: A154
102. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996; 91: 1758-65
103. Sontag SJ, Kugut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429-37
104. Robinson M, Campbell DR, Sontag S, et al. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy: lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 590-7
105. Hassall E, Israel D, Shepherd R, et al., and the International Pediatric Omeprazole Study Group. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000; 137: 800-7
106. Abdullah B, Gupta SK, Fitzgerald JF, et al. Long-term management of moderate/severe peptic esophagitis in children/adolescents: H2 blocker vs proton pump inhibitor (PPI) [abstract]. Gastroenterology 1998; 114: A51
107. Zimmermann AE, Walters JK, Katona BG, et al. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001; 23: 660-78
108. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastrooesophageal reflux disease in childhood. Dig Liver Dis 2000; 32: 660-6
109. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1397-402
110. Cucchiara S, Borrelli O, Gaudiello G, et al. Lansoprazole in children with severe gastroesophageal reflux disease: effect on gastric acidity, esophagitis and clinical outcome [abstract]. Gastroenterology 1999; 116: A142
111. Cucchiara S, Minella R, Campanozzi A, et al. Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig Dis Sci 1997; 42: 293-9
112. Nelis GF, Westerveld BD. Treatment of resistant reflux oesophagitis in children with omeprazole. Eur J Gastroenterol Hepatol 1990; 2: 215-7
113. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149: 267-71
114. Martin PB, Imong SM, Krischer J, et al. The use of omeprazole for resistant oesophagitis in children. Eur J Pediatr Surg 1996; 6: 195-7
115. De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997; 24: 528-32
116. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, et al. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998; 152: 1113-8
117. Strauss RS, Calenda KA, Dayal Y, et al. Histological esophagitis: clinical and histological response to omeprazole in children. Dig Dis Sci 1999; 44: 134-9
118. Alliet P, Raes M, Gillis P, et al. Treatment of refractory ulcerative oesophagitis with omeprazole [letter]. Arch Dis Child 1993; 68: 526
119. Gupta SK, Tolia V, Heyman MK, et al. Adolescent patients with gastroesophageal reflux disease: results from a randomized trial of lansoprazole [abstract]. Gastroenterology 2000; 118 (9): A1242
120. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of GERD in children [abstract]. Am J Gastroenterol 2000; 85 (9): A122
121. Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998; 27: 568-79
122. Colletti RB, Hassall E, Heyman MB, et al. Use of proton pump inhibitors (PPIs) by pediatric gastroenterologists [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: 414
123. Scott Levin & Associates. IMS America prescription audit. Newtown (PA): Scott Levin Audit, 2000
124. Mohiuddin MA, Pursnani KG, Katzka DA, et al. Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules. Dig Dis Sci 1997; 42: 715-9
125. Zimmermann AE, Walters JK, Katona B, et al. Alternative methods of proton pump inhibitor administration. Consult Pharm 1997; 12: 990-8
126. Chun AHC, Erdman K, Zhang Y, et al. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. Clin Ther 2000; 22: 231-6
127. Chun AHC, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 833-42
128. Doan TT, Wang Q, Griffin JS, et al. Comparable pharmacokinetics and pharmacodynamics of lansoprazole oral capsule and suspension in healthy subjects. Am J Health Syst Pharm 2001; 58: 1512-9
129. Sharma VK, Peyton B, Spears T, et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887-92
130. Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56 (23 Suppl.): S18-21
131. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension, a liquid formulation of lansoprazole, effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94 (7): 1813-7
132. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes. Curr Opin Pediatr 1995; 7: 220-33
133. Jacqz-Aigrain E, Bellaich M, Faure C, et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994; 47: 181-5
134. Kato S, Ebina K, Fojii K, et al. Effect of omeprazole in the treatment of refractory acid related disease in childhood: endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996; 128: 415-21
135. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000; 95: 3101-6
136. Regardh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 1986; 118: 99-104
137. Regardh CG, Gabrielsson M, Hoffman KJ, et al. Pharmacokinetics and metabolism of omeprazole in animals and man: an overview. Scand J Gastroenterol Suppl 1985; 108: 79-94
138. Cederberg C, Rohss K, Lundborg L, et al. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 179-84
139. Cederberg C, Thomson AB, Mahachai V, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913-8
140. Oosterhuis B, Jonkman JH, Andersson T, et al. No influence of single intravenous doses of omeprazole on theophylline kinetics. J Clin Pharmacol 1992; 32: 470-5
141. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002; 71 (5): 359-67
142. Hendriks HG, van Kreel B, Forget PP. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2001; 33: 260-5
143. Freston JW. Long-term acid control and proton pump inhibitors: interaction and safety issues in perspective. Am J Gastroenterol 1997; 92 (4 Suppl.): 51-57S
144. Freston JW, Rose PA, Heller CA, et al. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999; 20: 195-205
145. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9
146. Koop H, Naumann-Koch C, Arnold R. Effect of omeprazole on serum gastrin levels: influence of age and sex. Gastroenterology 1990; 28: 603-5
147. Freston JW, Borch K, Brand SJ, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Dig Dis Sci 1995; 40 (2 Suppl.): 50-62S
148. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990; 19: 141-53
149. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002. In press
150. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30
151. Sachs G. The safety of omeprazole: true or false. Gastroenterology 1994; 106: 1400-1
152. Lamberts R, Creutzfeldt W, Striber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104: 1356-70
153. Castell DO, Richter JE, Robinson M, et al., and the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57
154. Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole [abstract]. Gastroenterology 1995; 108: A121
155. Israel DM, Dimmick JE, Hassall E. Gastric polyps in children on omeprazole [abstract]. Gastroenterology 1995; 108: A110
156. Lee SW, Lieberman DA, Ippoliti AD, et al. Changes in the parietal cell mass after long term therapy with high dose omeprazole in Barrett's esophagus (BE): a two year prospective study [abstract]. Gastroenterology 1996; 110: A173
157. Weinstein WM, Ang ST, Ippolitit AF, et al. Fundic gland polyps in patients on long term omeprazole therapy: a light and electron microscopic study of the gastric mucosa [abstract]. Gastroenterology 1994; 106: A210
158. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000
159. Bachmann KA, Sullivan TJ, Jauregui L, et al. Drug interactions of H2-receptor antagonists. Scand J Gastroenterol Suppl 1994; 206: 14-9
160. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacother 1996; 31 (1): 9-28
161. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 Suppl. 1: S21-5
162. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79-85
163. Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51-4
164. Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 1996; 42: 157-62
165. Sutfin T, Balmer K, Bostrom N, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84
166. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509-12
167. Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-83
168. Cavanaugh JH, Karol MD. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone. J Clin Pharmacol 1996; 36: 1064-71
169. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235-41
170. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543-5
171. Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-6
172. Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329-33
173. Petersen K-U. Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 1-9
174. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21 (3): 195-212
175. Braeckman RA, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on a warfarin pharmacokinetics and anticoagulation effect in healthy subjects [abstract]. Pharm Res 1991; 8 (10 Suppl.): S295
176. Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady state warfarin metabolism [abstract]. Gastroenterology 1991; 100 (5 Pt 2): A40
177. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458-63
178. Karol MD, Mayersohn M, Eason CJ, et al. Evaluation of interaction potential between lansoprazole and clarithromycin (Biaxin®) in normal subjects [abstract]. 60th Annual Meeting of the American College of Gastroenterology; 1998 Oct 16-18; New York
179. Cavanaugh JH, Schneck DW, Mukherji D, et al. Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics [abstract]. Gastroenterology 1994; 106 (4): A4
180. Granneman GR, Karol MD, Locke CS, et al. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460-4
181. Pan WJ, Goldwater DR, Zhang Y, et al. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline. Aliment Pharmacol Ther 2000; 14: 345-52
182. Ko JW, Jang IJ, Shin JG, et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999; 65: 606-14
183. Karol MD, Locke CS, Cavanaugh JH. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol 1999; 39: 1283-9